Skip to main content
main-content

Semaglutide (Investigational)

News

11-13-2020 | Semaglutide | News

Semaglutide treatment may reverse NASH

Treatment with semaglutide can lead to resolution of nonalcoholic steatohepatitis in people with or without type 2 diabetes, show phase 2 trial findings, although a question mark remains over its effect on fibrosis.

09-28-2020 | EASD 2020 | Conference coverage | News

Semaglutide may offer renoprotection in type 2 diabetes

Semaglutide has the potential to improve kidney outcomes in people with type 2 diabetes, a post-hoc analysis of the SUSTAIN 1–7 trials shows.

04-24-2020 | Semaglutide | Highlight | News

PIONEER 9, 10 confirm oral semaglutide efficacy in Japanese population

Results of the PIONEER 9 and 10 trials show that oral semaglutide is efficacious in Japanese people with type 2 diabetes.

Read more

Related topics

Superior

Related

Opinion

05-06-2020 | Type 2 diabetes | Editorial | Article

Oral semaglutide: A technical triumph, with caveats

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide.

11-04-2016 | Clinical trial | Editorial | Article

My EASD 2016 Highlights: From Paleolithic diets to the artificial pancreas

Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.

In depth

07-03-2019 | Semaglutide | At a glance | Article

A quick guide to the PIONEER trials

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

10-17-2017 | GLP-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

Journal articles and book chapters

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

Image Credits